Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.

At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

Lundbeck announced the designation today and said it is expanding an ongoing phase I/II clinical open label trial of the investigational mAb in adults with classic CAH.

ADA 2025: The combination of the GLP-1 RA and novel monoclonal antibody yielded 92.8% of total weight loss from fat mass and 22.1% decrease in baseline weight.

Your daily dose of the clinical news you may have missed.

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.